       Document 0003
 DOCN  M9640003
 TI    Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa.
       Uganda Kaposi's Sarcoma Study Group.
 DT    9604
 AU    Chang Y; Ziegler J; Wabinga H; Katangole-Mbidde E; Boshoff C; Schulz T;
       Whitby D; Maddalena D; Jaffe HW; Weiss RA; Moore PS; Department of
       Pathology, Columbia University, New York, NY, USA.
 SO    Arch Intern Med. 1996 Jan 22;156(2):202-4. Unique Identifier : AIDSLINE
       MED/96136002
 AB    BACKGROUND: Endemic Kaposi's sarcoma (KS) is a clinically and
       epidemiologically distinct human immunodeficiency virus negative form of
       KS occurring in Africa. Kaposi's sarcoma is now the most frequently
       reported cancer in some areas of Africa. OBJECTIVE: To determine if a
       KS-associated herpesvirus (KSHV) is present in both endemic
       HIV-seronegative and HIV-seropositive KS lesions from African patients.
       METHODS: Paraffin-embedded tissue specimens from Ugandan patients with
       KS and non-KS tumor control patients attending a university-based
       oncology clinic were examined in a blinded case-control study. Tissue
       DNA specimens were examined for detectable KSHV genome by nested
       polymerase chain reaction performed at two independent laboratories.
       RESULTS: We identified KSHV in 17 (85%) of 20 KS tissue specimens from
       HIV-seronegative patients and 22 (92%) of 24 KS tissue specimens from
       HIV-infected persons. Kaposi's sarcoma lesions from four HIV-infected
       persons and four HIV-seronegative persons were positive for KSHV. Unlike
       previous studies in North America and Europe, three (14%) of 22 non-KS
       cancer control patients' tissue specimens were also positive for KSHV
       that resulted in an overall odds ratio of 49.2 (95% confidence interval,
       9.1 to 335) for detecting KSHV in KS lesions from patients in Uganda.
       CONCLUSION: As in North America and Europe, KSHV infection is strongly
       associated with both HIV-seropositive and HIV-seronegative KS in Africa.
       However, it is likely that infection with this virus is more highly
       prevalent in Uganda.
 DE    Case-Control Studies  DNA, Viral/ISOLATION & PURIF
       Herpesviridae/GENETICS/*ISOLATION & PURIF  Human  HIV Seronegativity
       HIV Seropositivity/*COMPLICATIONS  Odds Ratio  Polymerase Chain Reaction
       Sarcoma, Kaposi's/*VIROLOGY  Single-Blind Method  Support, Non-U.S.
       Gov't  Support, U.S. Gov't, Non-P.H.S.  Support, U.S. Gov't, P.H.S.
       Uganda  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

